Duchenne muscular dystrophy

Conference speaker
#Antibody #Antisense Oligonucleotides (ASOs) #Duchenne muscular dystrophy #Sapreme Therapeutics

Sapreme shares “unprecedented” preclinical data for Duchenne candidate

Sapreme Therapeutics has shared new preclinical data from its lead Duchenne muscular dystrophy (DMD) programme, SPM-2551, at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place in Denver, Colorado, US.  SPM-2551 is intended to restore dystrophin to more than 15% of normal levels –… Read More

#News

FDA headquarters
#Capricor Therapeutics #Cardiomyopathy #Duchenne muscular dystrophy #FDA

FDA rejects Capricor Therapeutics’ Duchenne muscular dystrophy drug 

The US Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee has voted that available evidence does not support the effectiveness of Capricor Therapeutics’ Deramiocel for the treatment of cardiomyopathy in patients with Duchenne muscular dystrophy (DMD).  DMD is a rare and life-threatening disease for which no approved… Read More

#News #Regulatory

#Biopharma #Business #Duchenne muscular dystrophy #Immunology / Virology & Vaccines #Mitochondria #Obesity

DDW Highlights: 11 November 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s leading story came from a positive development in biopharma, with top companies… Read More

#Podcasts

#Biopharma #Business #Duchenne muscular dystrophy #Immunology / Virology & Vaccines #Mitochondria #Obesity

This week in Drug Discovery (3 – 7 November) 

News round-up for 3 – 7 November by Bruno Quinney, Content Team at DDW.    This week’s leading story is a positive development in biopharma, with top companies reporting market growth in Q3 of 2025. Elsewhere, new research could help combat yellow fever and weight loss, while £500,000 was awarded to a… Read More

#News

Duchenne muscular dystrophy
#Duchenne muscular dystrophy #Gene editing #Gene mutation #Gene therapy

Duchenne UK hands out £500,000 award to develop DMD therapy 

Duchenne UK has awarded £500,000 ($653,000) to biotech company MyoGene Bio to support the development of an innovative gene editing therapy for Duchenne muscular dystrophy (DMD).  The funding is part of Duchenne UK’s Therapeutic Call, a competitive initiative designed to support innovative research with the potential to deliver new treatments for DMD.  MyoGene Bio… Read More

#Business & Investment #News

Map of Canada
#Duchenne muscular dystrophy #Health Canada #Paediatrics #Santhera Pharmaceuticals

First Duchenne muscular dystrophy treatment approved in Canada

The first treatment for Duchenne muscular dystrophy (DMD) has been approved in Canada. Santhera Pharmaceuticals announced that Health Canada approved the company’s Agamree (vamorolone) therapy for DMD in patients four years and older. DMD is a rare inherited X-chromosome-linked disease primarily affecting males. It is characterised by inflammation which is… Read More

#News #Regulatory

#Clinical trials #Diabetes #Duchenne muscular dystrophy #HIV #Immunology / Virology & Vaccines #Obesity #Oncology

This week in drug discovery (4-8 August) 

News round-up for 4-8 August by DDW Senior Digital Content Editor Diana Turner. In the week that the US Department of Health and Human Services cancelled multiple programmes investigating mRNA vaccines, a number of other clinical trials have made the headlines. The top stories:… Read More

#News

DNA vector
#AAV #Duchenne muscular dystrophy #Gene therapy #Hansa Biopharma

Data supports imlifidase prior to gene therapy for Duchenne

Hansa Biopharma has announced topline results from three patients with Duchenne muscular dystrophy (DMD) treated with its imlifidase prior to receiving Sarepta’s Elevidys (delandistrogene moxeparvovec-rokl) in the SRP-9001-104 trial.  After one dose of imlifidase, three patients experienced a rapid reduction of IgG antibodies, to levels ≥95% less… Read More

#News

#Duchenne muscular dystrophy #Gene therapy #Restructuring #Sarepta Therapeutics

Sarepta Therapeutics focuses pipeline and cuts 36% of workforce

Sarepta Therapeutics has announced a strategic restructuring plan designed to prioritise high-value, high impact programmes, and support its long-term financial viability.   This plan includes a 36% workforce reduction, impacting approximately 500 employees, and an emphasis on near- and mid-term opportunities from the siRNA platform.  Several programmes, including most of the… Read More

#Business & Investment #News

Duchenne muscular dystrophy
#Duchenne muscular dystrophy #Phase I trial #Satellos Bioscience

Duchenne muscular dystrophy drug shows favourable PK profile

Satellos Bioscience has shared positive initial Phase I data for its small molecule drug candidate SAT-3247 at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas.  SAT-3247 is designed to address progressive muscle loss in Duchenne muscular dystrophy (DMD) patients by aiming to… Read More

#News

#Clinical trial #Duchenne muscular dystrophy #Gene therapy #REGENXBIO

Gene therapy positively impacts Duchenne disease trajectory

AFFINITY DUCHENNE, a multi-centre, open-label trial of gene therapy RGX-202 for Duchenne muscular dystrophy has dosed its first patient, REGENXBIO has announced. The company also revealed new, positive efficacy and safety data from the Phase I/II portion of the study, including the first functional data. Read More

#News

Heart
#Cardiovascular disease #Corticosteroids #Duchenne muscular dystrophy #Paediatrics #Santhera Pharmaceuticals

Vamorolone demonstrates unique action as a mineralocorticoid RA

Santhera Pharmaceuticals has announced positive results from the LIONHEART study, confirming vamorolone’s action as a mineralocorticoid receptor antagonist, which the company says sets it apart from other corticosteroids. The LIONHEART study in 30 healthy adult male subjects demonstrated a statistically significant increase in the urinary sodium/potassium… Read More

#News

#AAV #Clinical trial #Duchenne muscular dystrophy #Gene therapy #REGENXBIO

Positive Phase I/II trial data for Duchenne gene therapy

New data has revealed a robust microdystrophin expression from a pivotal dose of gene therapy RGX-202 for Duchenne muscular dystrophy (Duchenne). RGX-202 is an investigational one-time AAV therapeutic designed to deliver a novel microdystrophin gene that includes key regions of the naturally occurring dystrophin gene. Read More

#News

FDA headquarters
#Duchenne muscular dystrophy #FDA #Gene therapy #Roche #Sarepta Therapeutics

FDA expands gene therapy use in Duchenne muscular dystrophy

The US Food and Drug Administration (FDA) has expanded its approval for Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least four years of age. Confirming the functional benefits, the FDA granted traditional approval for ambulatory… Read More

#News #Regulatory

#AAV #AskBio #Duchenne muscular dystrophy #Gene editing #Giant axonal neuropathy #Haemophilia #Pompe disease

Podcast: The evolution and future of gene therapy

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dr… Read More

#News